56 related articles for article (PubMed ID: 26396134)
1. Novel 4-anilino-α-carboline derivatives induce cell death in nonadhesive breast cancer cells through inhibition of Brk activity.
Oelze M; Mahmoud KA; Sippl W; Wersig T; Hilgeroth A; Ritter CA
Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1052-5. PubMed ID: 26396134
[No Abstract] [Full Text] [Related]
2. Discovery of 4-anilino α-carbolines as novel Brk inhibitors.
Mahmoud KA; Krug M; Wersig T; Slynko I; Schächtele C; Totzke F; Sippl W; Hilgeroth A
Bioorg Med Chem Lett; 2014 Apr; 24(8):1948-51. PubMed ID: 24650640
[TBL] [Abstract][Full Text] [Related]
3. Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.
Ikeda O; Mizushima A; Sekine Y; Yamamoto C; Muromoto R; Nanbo A; Oritani K; Yoshimura A; Matsuda T
Cancer Sci; 2011 Apr; 102(4):756-61. PubMed ID: 21205088
[TBL] [Abstract][Full Text] [Related]
4. Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors.
Foudah AI; Sallam AA; Akl MR; El Sayed KA
Eur J Med Chem; 2014 Feb; 73():310-24. PubMed ID: 24487236
[TBL] [Abstract][Full Text] [Related]
5. STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation.
Ikeda O; Miyasaka Y; Sekine Y; Mizushima A; Muromoto R; Nanbo A; Yoshimura A; Matsuda T
Biochem Biophys Res Commun; 2009 Jun; 384(1):71-5. PubMed ID: 19393627
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.
Gariboldi MB; Ravizza R; Molteni R; Osella D; Gabano E; Monti E
Cancer Lett; 2007 Dec; 258(2):181-8. PubMed ID: 17920763
[TBL] [Abstract][Full Text] [Related]
7. Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage.
Harvey AJ; Pennington CJ; Porter S; Burmi RS; Edwards DR; Court W; Eccles SA; Crompton MR
Am J Pathol; 2009 Sep; 175(3):1226-34. PubMed ID: 19661439
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
[TBL] [Abstract][Full Text] [Related]
9. Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
Ludyga N; Anastasov N; Gonzalez-Vasconcellos I; Ram M; Höfler H; Aubele M
Mol Biosyst; 2011 May; 7(5):1603-12. PubMed ID: 21380407
[TBL] [Abstract][Full Text] [Related]
10. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.
Real PJ; Sierra A; De Juan A; Segovia JC; Lopez-Vega JM; Fernandez-Luna JL
Oncogene; 2002 Oct; 21(50):7611-8. PubMed ID: 12400004
[TBL] [Abstract][Full Text] [Related]
11. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress.
Uckun F; Ozer Z; Vassilev A
Br J Haematol; 2007 Feb; 136(4):574-89. PubMed ID: 17367410
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of β-Carboline-Based N-Heterocyclic Carbenes and Their Antiproliferative and Antimetastatic Activities against Human Breast Cancer Cells.
Dighe SU; Khan S; Soni I; Jain P; Shukla S; Yadav R; Sen P; Meeran SM; Batra S
J Med Chem; 2015 Apr; 58(8):3485-99. PubMed ID: 25835200
[TBL] [Abstract][Full Text] [Related]
14. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
15. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of the JAK2/PI3K-mediated signaling activation is involved in Taiwan cobra cardiotoxin III-induced apoptosis of human breast MDA-MB-231 cancer cells.
Lin KL; Su JC; Chien CM; Chuang PW; Chang LS; Lin SR
Toxicon; 2010 Jun; 55(7):1263-73. PubMed ID: 20144642
[TBL] [Abstract][Full Text] [Related]
17. Protein tyrosine kinase, JNK, and ERK involvement in pseudolaric acid B-induced apoptosis of human breast cancer MCF-7 cells.
Yu JH; Wang HJ; Li XR; Tashiro S; Onodera S; Ikejima T
Acta Pharmacol Sin; 2008 Sep; 29(9):1069-76. PubMed ID: 18718176
[TBL] [Abstract][Full Text] [Related]
18. STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells.
Yi EH; Lee CS; Lee JK; Lee YJ; Shin MK; Cho CH; Kang KW; Lee JW; Han W; Noh DY; Kim YN; Cho IH; Ye SK
Mol Cancer Res; 2013 Jan; 11(1):31-42. PubMed ID: 23074171
[TBL] [Abstract][Full Text] [Related]
19. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells.
Gritsko T; Williams A; Turkson J; Kaneko S; Bowman T; Huang M; Nam S; Eweis I; Diaz N; Sullivan D; Yoder S; Enkemann S; Eschrich S; Lee JH; Beam CA; Cheng J; Minton S; Muro-Cacho CA; Jove R
Clin Cancer Res; 2006 Jan; 12(1):11-9. PubMed ID: 16397018
[TBL] [Abstract][Full Text] [Related]
20. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
